[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368000-105":59,"doc-detail-368000-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","public-health-impact-and-cost-effectiveness-of-implementing-gender-neutral-immunization-with-the-nonavalent-human-papillomavirus-vaccine-in-south-korea","Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea","","This study assessed the impact and cost-effectiveness of gender-neutral immunization with the nonavalent human papillomavirus (HPV) vaccine in South Korea. An established dynamic transmission model was adapted to South Korean HPV epidemiology and compared vaccinating both girls and boys with the nonavalent vaccine versus vaccinating girls only with the currently used quadrivalent program. Gender-neutral vaccination projected large reductions in CIN1, CIN2/3, cervical cancer cases and deaths, plus additional HPV-related cancer and disease burden reductions, and yielded an incremental cost-effectiveness ratio below the national threshold under base-case assumptions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/public-health-impact-and-cost-effectiveness-of-implementing-gender-neutral-immunization-with-the-nonavalent-human-papillomavirus-vaccine-in-south-korea/368000/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/public-health-impact-and-cost-effectiveness-of-implementing-gender-neutral-immunization-with-the-nonavalent-human-papillomavirus-vaccine-in-south-korea/368000.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to evaluate for South Korea?","Question",{"text":112,"@type":113},"It evaluated the public health impact and cost-effectiveness of implementing gender-neutral immunization using the nonavalent HPV vaccine.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the model compare vaccination strategies?",{"text":117,"@type":113},"It compared vaccinating both girls and boys with the nonavalent HPV vaccine against the current program vaccinating girls only with the quadrivalent vaccine.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results suggest about health outcomes and costs?",{"text":121,"@type":113},"Gender-neutral vaccination was projected to prevent substantial HPV-related disease outcomes in both females and males, and the incremental cost-effectiveness ratio was below the accepted cost-effectiveness threshold under base-case assumptions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368000,1790203001,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE     \nPublic health impact and cost-effectiveness of implementing  \ngender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea  \nSangrak Bae a, Ji Hyun Park b, Seyoung Oh c, Gyongseon Yang c, Wei (Vivian) Wang d, Andrew Pavelyeve, and Isaya Sukarom f  \naDepartment of Urology, Uijeongbu St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; bMarket Access, MSD Korea, Seoul, South Korea; cGlobal Medical and Scientific Affairs, MSD Korea, Seoul, South Korea; dOutcomes Research, Merck & Co., Inc., Rahway, NJ, USA; e Health Econonomics and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USA; fOutcomes Research, Regional Asia Pacific, MSD Thailand, Bangkok, Thailand  \nABSTRACT  \nThis study assessed the impact and cost-effectiveness of gender-neutral immunization with the nonavalent human papillomavirus (HPV) vaccine in South Korea. An established dynamic transmission model of HPV epidemiology was adapted to the South Korean population. Vaccinating both girls and boys with the nonavalent HPV vaccine was compared to the currently administered program of vaccinating girls only with the quadrivalent vaccine. Compared to vaccination of girls only with the quadrivalent HPV vaccine, gender-neutral vaccination with the nonavalent HPV vaccine was projected to prevent 1,282,415 cases of cervical intraepithelial neoplasia grade 1 (CIN1), 918,384 cases of CIN2/3, 36,248 cases of cervical cancer, and 9,313 cervical cancer deaths in females over 100 years. Gender-neutral vaccination was projected to reduce HPV-related vaginal, vulvar, anal, and head & neck cancers in females by 4.8–8.2%, in addition to reductions of 14.6% and 15.8% in genital warts and recurrent respiratory papillomatosis, respectively. In males, gender-neutral vaccination was projected to prevent 666,182 cases of genital warts, 7,422 cases of RRP, 995 cases of anal cancer, 2,441 cases of head & neck cancer, and 122 cases of penile cancer. The incremental cost-effectiveness ratio (ICER) was ₩38.9 million per quality-adjusted life year (QALY), which is below the accepted costeffectiveness threshold in South Korea. These findings suggest that gender-neutral vaccination with the nonavalent HPV vaccine would reduce the public health burden of HPV disease in both females and males in South Korea and would be cost-effective under base case assumptions about vaccine price and coverage of boys.  \nARTICLE HISTORY  \nReceived 13 May 2025 Revised 2 October 2025 Accepted 26 October 2025  \nKEYWORDS  \nCancer; gender-neutral vaccination; human papillomavirus;  \npapillomavirus vaccines; 9vHPV  \nIntroduction  \nWorldwide, human papillomavirus (HPV) infection is responsible for 25–50% of cases ofvulvar, penile, and head & neck cancers (primarily oropharyngeal, but also oral and laryngeal), 80–90% of cases of vaginal and anal cancers, 1 and virtually all cases of cervical cancer.2  \nHPV strains are categorized as either low-risk (benign) or high-risk (oncogenic) .3 Low-risk types 6 and 11 are responsible for approximately 90% of genital wart cases and most cases of recurrent respiratory papillomatosis (RRP) .3,4 High-risk HPV types, which include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, are primarily responsible for precancerous and cancerous lesions of the anogenital area in both sexes. 1,5 In South Korea, the prevalence of HPV infection has been estimated at 10–15% among young women aged 19–20 and at 38.8% among women with sexual experience.6,7 A meta-analysis also found that HPV infection was present in 20.4% of women with a normal cervix, 85.6% of those with high-grade cervical intraepithelial neoplasia (CIN2/3/CIS), and 88.3% of those with cervical cancer, with HPV-16, 18, and 58 among the most common high-risk types in South Korea.8  \nCONTACT Isaya Sukarom  [isaya.sukarom@msd.com](isaya.sukarom@msd.com)  MSD Thailand, 999/9 The Offices at CentralWorld, Floor 37th, Rama I Road, Pathu","cbCaikJ1rUsOhzQV","https://ap.wps.com/l/cbCaikJ1rUsOhzQV","pdf",793765,12,"English","# Abstract\n# Introduction\n## HPV burden and risk types in South Korea\n## Existing HPV vaccination programs","[{\"question\":\"What was the study designed to evaluate for South Korea?\",\"answer\":\"It evaluated the public health impact and cost-effectiveness of implementing gender-neutral immunization using the nonavalent HPV vaccine.\"},{\"question\":\"How did the model compare vaccination strategies?\",\"answer\":\"It compared vaccinating both girls and boys with the nonavalent HPV vaccine against the current program vaccinating girls only with the quadrivalent vaccine.\"},{\"question\":\"What did the results suggest about health outcomes and costs?\",\"answer\":\"Gender-neutral vaccination was projected to prevent substantial HPV-related disease outcomes in both females and males, and the incremental cost-effectiveness ratio was below the accepted cost-effectiveness threshold under base-case assumptions.\"}]","Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea | PDF",1790174288,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8cef5408a9018295fecb5f3accb63f4.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/309c4b9360fa2dc36a73b624fb034470.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35f74d12daec1d0d118a1044b3395d7.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc86ea60725bdfe63fdb61e75e7b3472.webp",980,1306]